Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Indication
Institution
Department
Principal Investigator
Protocol Title
TMU-JIRB No. Protocol Title Indication Institution Department Principal Investigator Contact
N202208003 Patient-Reported Outcomes of Benralizumab in Real-World Use in Severe Eosinophilic Asthma Patients in Taiwan (BEAT) Asthma SHH Pulmonary Medicine

Chen Kuan-Yuan

 02-6620-2589
N202208028 A Phase III, Randomised, Open- label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato- DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combin ation With Platinum-based Chemotherapy for the First- line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionabl e Genomic Alterations (D926NC00001; AVANZAR) Lung Cancer SHH Pulmonary Medicine

Kang-Yun Lee

 02-6620-2589
N202210056 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Oral Ozanimod to Evaluate Efficacy and Long-term Safety in Chinese Participants with Moderately to Severely Active Ulcerative Colitis (UC) Ulcerative Colitis (UC) SHH Gastroenterology

Ming-Yao Chen

 02-6620-2589
N202210086 A Phase I, Open-label, Dose-escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Modified Salmonella Typhimurium SGN1 Administered via Intratumoral Injection in Patients with Advanced Solid Tumors Solid tumors SHH Hematology and Oncology

Wei-Hong Cheng

 02-6620-2589
N202212013 A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Anifrolumab in Asian Participants with Active Systemic Lupus Erythematosus Systemic Lupus Erythematosus SHH Allergy, Immunology and Rheumatology

Yu-Sheng Chang

 02-6620-2589
N202212018 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis Myasthenia Gravis SHH Neurology

Hou-Chang Chiu

 02-6620-2589
N202303061 A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2) Lung Cancer SHH Pulmonary Medicine

Kang-Yun Lee

 02-6620-2589
N202303137 A Phase I/IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GMXANTHO in Healthy Volunteers and to Investigate its Efficacy and Safety Profile in Atopic Dermatitis Patients. Atopic Dermatitis SHH Dermatology

Chia-Lun Chou

 02-6620-2589
N202305029 A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA Ischemic stroke SHH Neurology

Lung Chan

 02-6620-2589
N202307004 A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH−]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy Breast Cancer SHH Hematology and Oncology

Tsu-Yi Chao

 02-6620-2589
1 2 3 4 5 6 / 6

TOP